Psychiatry International, published by MDPI, is a dynamic and open-access journal dedicated to advancing the field of psychiatry and mental health. Since its inception in 2020, this journal has emerged as a vital platform for the dissemination of innovative research and impactful insights across various subdisciplines, encompassing psychiatric nursing, general medicine, and neuroscience. With an E-ISSN of 2673-5318, Psychiatry International facilitates accessibility to research findings and fosters collaboration among researchers, healthcare professionals, and academics worldwide. The journal's alignment with modern Open Access principles reflects its commitment to enhancing the visibility and reach of psychiatric research. Despite being relatively new, it has demonstrated a promising standing in Scopus rankings, positioning itself within the top quartile for Nursing (Psychiatric Mental Health) and showing potential for growth in other related categories. By encouraging submissions that address the latest developments and challenges in mental health, Psychiatry International aims to catalyze progress in mental health awareness and intervention strategies, making it an essential resource for anyone engaged in the field.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

NEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.

Neurosciences is a premier academic journal dedicated to the exploration of neurological and psychiatric disorders, fostering an innovative exchange of ideas and research findings in these critical fields. Published by the Riyadh Armed Forces Hospital in Saudi Arabia, this interdisciplinary journal has consistently contributed to the advancement of knowledge since its inception in 2002 and is set to continue through 2024. With an ISSN of 1319-6138 and E-ISSN of 1658-3183, it is recognized for its emphasis on clinically relevant research in neurology and psychiatry, boasting a 2023 classification in the Q3 tier of both categories. Neurosciences encourages submissions that offer novel insights into mental health and neurological conditions, positioning itself as a vital resource for researchers, healthcare professionals, and students alike. Despite being unlisted as an open-access journal, it remains a respected outlet for peer-reviewed content, with Scopus rankings that highlight its growing influence within the scientific community. This journal serves as an essential platform for disseminating significant research that addresses the intricacies of the human brain and behavior.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.

Current Addiction Reports, published by SPRINGERNATURE, is a leading journal dedicated to the comprehensive study of addiction in its various dimensions, with a particular focus on the latest clinical developments and research in Clinical Psychology and Psychiatry and Mental Health. Since its inception in 2014 and through to 2024, the journal has established itself as a pivotal resource for researchers, professionals, and students alike, currently holding a prestigious Q1 ranking in both relevant categories. With an impressive Scopus rank of #46 in Clinical Psychology and #129 in Psychiatry and Mental Health, it occupies a significant position within the field, reflecting its commitment to high-quality scholarship and impactful findings. The journal offers open access options, ensuring that vital research is readily available to a global audience. By fostering a deeper understanding of addiction trends and innovative treatment methodologies, Current Addiction Reports plays an essential role in advancing knowledge and improving clinical practices.

European Archives of Psychiatry and Clinical Neuroscience is a prominent peer-reviewed journal published by Springer Heidelberg, focusing on the interdisciplinary aspects of psychiatry and clinical neuroscience. With an ISSN of 0940-1334 and an E-ISSN of 1433-8491, this journal provides a rigorous platform for innovative research spanning biological psychiatry, pharmacology, and various aspects of mental health. The journal boasts a distinguished impact factor that places it in the Q2 category for Biological Psychiatry and Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health as of 2023, reflecting its significant contribution to the field. Additionally, its Scopus rankings highlight its esteemed position among the top journals, particularly in Medicine and Neuroscience disciplines. Readers can access a wealth of valuable research articles, case studies, and reviews, crucial for advancing understanding and treatment within these vital fields. Initially converged in 1990, the journal continues to evolve and support scholarly dialogue until 2024 and beyond, making it an essential resource for researchers, clinicians, and students alike.

NORDIC JOURNAL OF PSYCHIATRY is a pivotal publication in the field of psychiatry and mental health, dedicated to advancing knowledge and fostering dialogue among researchers, clinicians, and students. Published by Taylor & Francis Ltd, this esteemed journal, with an ISSN of 0803-9488 and E-ISSN 1502-4725, serves as a platform for innovative research and critical reviews that address crucial mental health issues affecting Nordic populations and beyond. Its impact is underscored by a notable Q2 ranking in the Psychiatry and Mental Health category for 2023, along with a respectable position within the Scopus ranking at #268 out of 567. The journal has been a reliable source of scientific inquiry since its inception in 1947, and it aims to facilitate significant advancements in the understanding and treatment of psychiatric disorders. By providing access to high-quality research without open access options, NORDIC JOURNAL OF PSYCHIATRY remains a must-read for those dedicated to progressing mental health science in a global context.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.